Chemaxon blog
Filter by content type
Coupling stabilizers open KV1-type potassium channels
ABSTRACT: The opening and closing of voltage-gated ion channels are regulated by voltage sensors...
Certara and Chemaxon Announce Collaboration in Scientific Informatics Software
PRINCETON, N.J. — Certara, Inc., a global leader in biosimulation, and Chemaxon, a leading chemical...
Chemaxon’s response to CVE-2022-22965 and CVE-2022-22963
Summary of Chemaxon Actions: Chemaxon architects and engineering teams are actively investigating...
New year, New Beginning: Chemaxon announces new CEO, Richard Jones
Chemaxon, a leader in cheminformatics software development for life science research, announced the...
Chemaxon’s new logo
We are so happy to share Chemaxon’s new brand! It has been 24 years since we started, and from time...
ChemAxon now uses Okta, the world’s #1 identity platform. Update your profile now.
What does this change mean? An even more secure platform and smooth account handling for all...
ChemAxon’s response to CVE-2021-44228 (“Log4Shell”) together with CVE-2021-45046
Updated 3 January, 2022 We are continuing to remediate the Log4j Java library remote code execution...
Cheminfo Stories Virtual UGM 2021 Asia Pacific Edition: Deep dive in the future of chemical patent drafting and in-house IP management
Writing chemical patents with Markush claims is a time-consuming, complex and business-critical...
Cheminfo Stories 2021 Virtual UGM Asia Pacific Edition: Design of new compounds from the available chemical space
In computational compound design workflows, the analysis of the available chemical space is an...
Cheminfo Stories 2021 Virtual UGM | Boost analytical experiments with phys-chem properties
TRY CHEMICALIZE Log in for videos & slides
Cheminfo Stories 2021 Virtual UGM | Progress in developing virtual chemical space
Exploring virtual chemical spaces has an important role in various fields of cheminformatics...
Cheminfo Stories 2021 Virtual UGM | Enhancing Sibylla’s innovative drug discovery platform with ChemAxon
Sibylla's innovative pharmacological platform is aimed at discovering new drugs for untreatable...